SQ Innovation today announced that results of the SUBCUT HF II trial of its product Lasix® ONYU, will be presented at Heart Failure 2026, the annual congress of the Heart Failure Association (HFA) of ...
Total hip arthroplasty leads to the best outcomes in the treatment of moderate-to-severe hip osteoarthritis, according to a ...
Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six ...
Stocktwits on MSN
LGVN stock slips after hours as FDA flags concerns on rare heart defect trial design
The agency explicitly stated that the trial’s current primary endpoint is “not an appropriate endpoint to demonstrate efficacy.” ・As a result, the FDA no longer considers the study to be “pivotal.” ...
Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid’s integrated, multi-trial development ...
Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no pat ...
Global Phase 3, randomized, controlled trial comparing azenosertib to standard-of-care chemotherapy now enrollingASPENOVA designed as ...
Tesamorelin can selectively reduce visceral fat, as demonstrated in RCTs. But the real story is what it reveals about ...
Passage Bio, which has been working toward a registrational trial for a drug candidate whose indications include ...
Total hip arthroplasty leads to the best outcomes in the treatment of moderate-to-severe hip osteoarthritis, according to a ...
Data presented at ARVO 2026 show that high-dose gene therapy boosts central retinal sensitivity in X-linked retinitis ...
This randomized controlled trial (RCT) evaluated whether tailored cost information could reduce consumer inertia in selecting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results